Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II

Front Endocrinol (Lausanne). 2023 Oct 19:14:1317220. doi: 10.3389/fendo.2023.1317220. eCollection 2023.

Deborah L Burnett^{1

2}, Megan B Barnet^{1

2

3}, Ania Moxon¹, Venessa Tsang^{4

5}, Katherine Samaras^{2

6

7}

¹ Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
² School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, Australia.
³ Department of Medical Oncology, St Vincent's Hospital, Darlinghurst, NSW, Australia.
⁴ Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
⁵ Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW, Australia.
⁶ Department of Endocrinology, St Vincent's Hospital, Darlinghurst, NSW, Australia.
⁷ Clinical Obesity, Nutrition, and Adipose Biology Lab, Clinical Science Pillar, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

No abstract available

Keywords: CTLA -4; PD-1 - PD-L1 axis; cancer immunotherapy; immune check inhibitor (ICI); immune related adverse effects.

Publication types

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.